Speaker :

Dr. Mansi Shah, Medical Oncologist, Ahemdabad

PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate  palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive  patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer

Author: Antonio Llombart-Cussac

 Citation: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1007-1007

LBA19 - GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II  trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy  in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive  advanced breast cancer (ABC

Author: Joan Albanell

 Citation: Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 

 10.1016/annonc/annonc325